Hesperidin as a Potential Candidate for Improving the Response of Detroit 562 cells to Cisplatin—An In Vitro Study
1 Research Center for Pharmaco-Toxicological Evaluations, “Victor Babes” University of Medicine and Pharmacy Timisoara, 2 Eftimie Murgu Square, 300041 Timisoara, Romania; (D.S.); (I.S.); (A.S.)
2 Faculty of Pharmacy, “Victor Babes” University of Medicine and Pharmacy Timisoara, 2 Eftimie Murgu Square, 300041 Timisoara, Romania
3 Doctoral School, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square, No. 2, 300041 Timisoara, Romania
* Author to whom correspondence should be addressed.
Received: 13 Feb 2026 / Accepted: 13 May 2026 / Published: 15 Jun 2026
Abstract
Background: Oropharyngeal squamous cell carcinoma (OPSCC) is one of the most common cancers globally, occurring in all types of populations, but current therapy faces multiple barriers, urgently requiring new alternatives for improvement. Hesperidin (HSP) is a bioflavonoid with pleiotropic properties that has been mentioned in studies for enhancing response to chemotherapy, including in the case of cisplatin (CIS). Methods: Using Detroit 562 cells, HSP, CIS, and the combinatorial treatment of the two were examined by MTT assay, morphological analysis, and mitochondrial and nuclear assessment for 24 h. Results: The results showed that the combination of HSP+CIS produces superior effects, reducing cell viability by up to 16%and producing cell rounding and shrinkage and significant alterations in nuclei and mitochondria compared to individual treatments. Conclusions: HSP may be an important candidate in improving CIS cytotoxicity in Detroit 562 cells and could be considered a promising natural adjuvant. The combined treatment of the phytocompound and CIS led to superior outcomes, enhancing the effects of CIS.
Keywords: hesperidin; cisplatin; combinatorial treatment; oropharyngeal squamous cell carcinoma
OPEN ACCESS
This is an open access article distributed under the Creative Commons Attribution
License which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. (CC BY 4.0).
CITE
Sașco, D.; Dumitrel, Ș.-I.; Smultea, I.; Smeu, A. Hesperidin as a Potential Candidate for Improving the Response of Detroit 562 cells to Cisplatin—An In Vitro Study. JEPT 2026, 4, 3.
Sașco D, Dumitrel Ș-I, Smultea I, Smeu A. Hesperidin as a Potential Candidate for Improving the Response of Detroit 562 cells to Cisplatin—An In Vitro Study. JEPT. 2026; 4(1):3.
Sașco, Daniela; Dumitrel, Ștefania-Irina; Smultea, Ioan; Smeu, Andreea. 2026. "Hesperidin as a Potential Candidate for Improving the Response of Detroit 562 cells to Cisplatin—An In Vitro Study." JEPT 4, no. 1: 3.
Not implemented
SHARE
